bioRxiv Science⌕ Search

Biology subjects

Freistaedter, A.

Publications and source records attributed to Freistaedter, A..

2 recordsLinked to original sources

ZDHHC17–Mediated Palmitoylation of Hepatitis E Virus ORF3 Protein Regulates Vectorial Trafficking in Polarized Epithelial Cells

The hepatitis E virus (HEV) is a leading cause of acute hepatitis worldwide and is transmitted enterically along the gut-liver axis. Epithelial cell polarity in the gut and liver plays a critical role in HEV transmission. In intestinal epithelial cells, HEV enters through the apical membrane and is released basolaterally to access the bloodstream, whereas in hepatocytes, the virus enters basolaterally and is secreted apically into the bile duct. In this study, we sought to identify the viral and host determinants governing directional HEV secretion in both tissue types. Using polarized intestinal and hepatocyte models, we found that the small phosphoprotein ORF3, which is essential for progeny secretion, localizes predominantly to the apical membrane, in contrast to the ORF2 capsid protein. We further identified the palmitoyltransferase ZDHHC17 as a specific ORF3 interactor that mediates its apical localization and promotes HEV progeny release. Using automated cell segmentation and quantitative image analysis, we screened a panel of ORF3 mutants and found that positively charged residues within the N-terminus regulate membrane association. In addition, we identified a conserved PIFIQP motif that mediates the critical interaction with the ankyrin repeat domain (ARD) of ZDHHC17. Leveraging this interaction, we generated high-confidence structural models of ORF3 in complex with the ZDHHC17 ARD using AlphaFold. These models, further validated by molecular dynamics simulations, revealed additional ORF3 residues involved in the interaction. Collectively, our findings define key mechanisms underlying directional HEV release and provide broader insights into trafficking processes in polarized epithelial cells.

Cell Biology↗

The nucleotide analog bemnifosbuvir inhibits hepatitis E virus replication in preclinical models

BackgroundHepatitis E virus infections remain a global health concern. Immunocompromised patients are at an increased risk to develop chronic HEV infection and thereby severe liver disease. Current off-label regimens are suboptimal with treatment failure being reported. Therefore, there is an urgent need for an effective anti-HEV treatment. ObjectiveIn this study, we aimed to identify potent inhibitors of HEV replication. DesignWe developed a rapid, image-based screening platform based on a full-length HEV fluorescence reporter virus and screened a nucleotide/nucleoside analog library. The identified lead candidate was validated in authentic hepatocyte culture systems, as well as in a gerbil infection model. ResultsBemnifosbuvir (BEM), previously characterized as a nucleotide analog with activity against other RNA viruses, efficiently suppressed HEV replication in vitro and in vivo in a dose-dependent manner, with minimal cytotoxicity at effective concentrations. Combining BEM with ribavirin, the off-label drug given to chronic HEV patients, resulted in an additive antiviral effect against HEV. We found that HEV-3 remains susceptible to inhibition by BEM over an extended treatment period, reducing concerns about the rapid development of viral resistance. Importantly, BEM significantly reduced HEV viral loads and liver inflammation in a gerbil infection model. ConclusionsGiven BEMs favorable safety profile in preclinical and clinical settings, our results suggest investigating its efficacy in patients with chronic HEV infection.

microbiology↗